Product Information
TADALAFIL 20 MG TABLET is a generic product labeled by Upsher-Smith Laboratories LLC, priced at $0.1671 per EA under NDC 24979073006. Its NADAC has been published 91 times since Jan 8, 2025.
FDA first approved this application on Mar 26, 2019. Its Orange Book therapeutic-equivalence code is AB1 — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
20 mg/1
Manufacturer
Upsher-Smith Laboratories LLCNDC
24979073006
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
TADALAFILApproval Type
Generic (ANDA)
FDA Application
ANDA210420FDA Approved
3/26/2019
TE Code
AB1
On Market Since
4/7/2024
Pharmacological Classes
Price Statistics
The NADAC for TADALAFIL 20 MG TABLET has been published 91 times since Jan 8, 2025, and over the history we have for it it has declined 17.2%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1671 per EA |
|---|---|
| All-time high | $0.2307 (May 14, 2025) |
| All-time low | $0.1582 (Aug 19, 2026) |
| 52-week high | $0.2116 |
| 52-week low | $0.1582 |
| Median price | $0.2051 |
| Average price | $0.1994 |
| Largest weekly change | +12.8% (Feb 19, 2025) |
| Weeks tracked | 91 |
| Tracking since | Jan 8, 2025 |
Generic Alternatives
The matcher finds 18 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 12% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Upsher-Smith Laboratories LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Tadalafil market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Phosphodiesterase 5 Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of TADALAFIL 20 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for TADALAFIL 20 MG TABLET, manufactured by Upsher-Smith Laboratories LLC, is $0.1671 per EA (NDC 24979073006), effective Sep 30, 2026.
How has the price of TADALAFIL 20 MG TABLET changed over time?
Over the history we have for it, the NADAC for TADALAFIL 20 MG TABLET has declined 17.2%. It has been tracked across 91 weekly CMS publications since Jan 8, 2025.
What are the highest and lowest recorded NADAC prices for TADALAFIL 20 MG TABLET?
Since Jan 8, 2025, the NADAC for TADALAFIL 20 MG TABLET has ranged from a low of $0.1582 (Aug 19, 2026) to a high of $0.2307 (May 14, 2025), with a median of $0.2051 per EA.
Are there cheaper alternatives to TADALAFIL 20 MG TABLET?
Yes. 18 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, ALYQ 20 MG TABLET, is $0.1463 per EA — about 12% below TADALAFIL 20 MG TABLET.
Who manufactures TADALAFIL 20 MG TABLET?
TADALAFIL 20 MG TABLET (NDC 24979073006) is labeled by Upsher-Smith Laboratories LLC, and CMS classifies it as a generic product.